Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CCR6 | P51684 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.30 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.30 |
| ▸ | VEGFA | P15692 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21596828 | 0.84 | TRPV4 (0.35) | TRPV4ADORA1ADORA2AMEN1ALDH1A1 | |
| SCHEMBL24413387 | 0.76 | TRPV4 (0.54) | TRPV4EGLN2EPAS1VEGFA | |
| SCHEMBL13863736 | 0.76 | TRPV4 (0.54) | TRPV4EGLN2EPAS1 | |
| SCHEMBL17365726 | 0.75 | GRIN1 (0.34) | MEN1ALDH1A1LMNAHSP90AA1PKM | |
| SCHEMBL559898 | 0.75 | TRPV4 (0.48) | TRPV4LMNAHTT | |
| SCHEMBL186585 | 0.74 | TRPV4 (0.52) | TRPV4ADORA1ADORA2AMEN1ALDH1A1 | |
| SCHEMBL29639661 | 0.72 | EPAS1 (0.45) | EPAS1VEGFA | |
| SCHEMBL24816740 | 0.72 | TRPV4 (0.41) | TRPV4EGLN2 | |
| SCHEMBL18036193 | 0.72 | EGLN2 (0.36) | ADORA1ADORA2AEGLN2 | |
| SCHEMBL31535909 | 0.72 | TRPV4 (0.37) | TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062393-A1 | Compounds | CTXT PTY LTD (AU) | 2026-03-05 | — | — | US | disclosed |
| US-12365655-B2 | Compounds | CTXT PTY LTD (AU) | 2025-07-22 | — | — | US | disclosed |
| CN-112334466-B | Compounds of formula (I) | CTXT私人有限公司 | 2025-05-30 | — | — | CN | disclosed |
| EP-4335439-A2 | COMPOUNDS | CTXT PTY LTD (AU) | 2024-03-13 | — | — | EP | disclosed |
| EP-3810602-B1 | COMPOUNDS | CTXT PTY LTD (AU) | 2023-11-01 | — | — | EP | disclosed |
| EP-3810602-B1 | COMPOUNDS | CTXT PTY LTD (AU) | 2023-11-01 | — | — | EP | disclosed |
| US-20220153710-A1 | Compounds | CTXT PTY LTD (AU) | 2022-05-19 | — | — | US | disclosed |
| US-20220153710-A1 | Compounds | CTXT PTY LTD (AU) | 2022-05-19 | — | — | US | disclosed |
| EP-3810602-A1 | COMPOUNDS | CTXT Pty Limited (AU) | 2021-04-28 | — | — | EP | disclosed |
| US-20200039945-A1 | Compounds | CTXT PTY LIMITED (AU) | 2020-02-06 | — | — | US | disclosed |
| US-20200039945-A1 | Compounds | CTXT PTY LIMITED (AU) | 2020-02-06 | — | — | US | disclosed |
| WO-2019243491-A1 | COMPOUNDS | CTXT PTY LIMITED (AU) | 2019-12-26 | — | — | WO | disclosed |
| WO-2019243491-A1 | COMPOUNDS | CTXT PTY LIMITED (AU) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153710-A1 | Compounds | SLC10A1, ABCB11, PCSK9 | TRPV4 908/4885ADORA1 2465/4885ADORA2A 4338/4885 |
| US-20200039945-A1 | Compounds | SLC10A1, ABCB11, PCSK9 | TRPV4 909/4885ADORA1 2462/4885ADORA2A 4335/4885 |
| US-20260062393-A1 | Compounds | SCN2B, ABCB11, SCN1B | TRPV4 1449/4885ADORA1 622/4885ADORA2A 2191/4885 |
| US-12365655-B2 | Compounds | SLC10A1, ABCB11, PCSK9 | TRPV4 909/4885ADORA1 2462/4885ADORA2A 4335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.